To read the full story, subscribe or sign in.

Astellas, Frequency in worldwide agreement targeting hearing loss

July 18, 2019

Astellas Pharma Inc. and Frequency Therapeutics Inc. have agreed to develop and commercialize Frequency's regenerative therapeutic candidate, FX-322, to treat sensorineural hearing loss (SNHL).

BioWorld Deals and M&A Collaboration

Today's news in brief

BioWorld

BioWorld briefs for Nov. 21, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for November 21, 2024.

J&J’s Ottava robotic system approved for US pivotal trial

BioWorld MedTech

Johnson & Johnson received U.S. FDA investigational device exemption to begin the pivotal clinical trial for the Ottava robotic surgical system. If the trial goes...

Illustration of Microglia cells (red) in Alzheimer´s disease

Less microglia activity may improve APOE4’s effect in Alzheimer’s

BioWorld

Reducing microglial activity in the presence of apolipoprotein E4 (APOE4) has uncovered a mechanism associated with the deposition of misfolded amyloid and tau in...

‘Evo’ AI can design complete genomes

BioWorld Science

The development of new machine learning tools like Alphafold and Rfdiffusion has allowed scientists to predict the structure of proteins and design them for drug...

Upgrade your daily dose of biopharma and medtech news

Astellas, Frequency in worldwide agreement targeting hearing loss